Stock Analysis
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis
Rhythm Pharmaceuticals, Inc. (RYTM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Rhythm Pharmaceuticals, Inc. (RYTM) currently has an AIQ Score of 62/100, indicating a neutral setup. Momentum is the strongest factor at 72/100. Value is the weakest current factor at 52/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RYTM at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $115.02 |
| AIQ Score | 62/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $7.94B |
| P/E Ratio (TTM) | -39.66 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.61 |
| Revenue (Q3 FY2026) | $92.13M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.24 |
| Volume | 1.16M |
| 52-week range | $74.50-$122.20 |
| RSI 14 | 66.28 |
| 50-Day SMA | $96.88 |
| 200-Day SMA | $97.24 |
| Analyst Price Target | $136.33 |
| Next Earnings | Feb 25, 2027 |
RYTMRhythm Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum72
- Value52
- Quality60
- Risk resilience57
- Sentiment—
RYTM Stock Analysis Summary
Rhythm Pharmaceuticals, Inc. (RYTM) currently has an AIQ Score of 62/100, indicating a neutral setup. Momentum is the strongest factor at 72/100. Value is the weakest current factor at 52/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RYTM has AIQ Score of 62/100 with Momentum base of 72/100 and fading Value at 52/100. Wait for component alignment before adding exposure.
Momentum (72/100) leads while Value (52/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 4.70% stock move · RYTM classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RYTM Bullish or Bearish Right Now?
RYTM currently has a neutral overall setup. Momentum is the strongest factor at 72/100, while Value is weakest at 52/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 72/100.
- - Price is +18.72% above its 50-day SMA.
- - Analyst target implies +18.53% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (38 vs 5).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
RYTM's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 3 neutral, and 5 sell votes. RYTM's 14-day RSI is 66.28, which places the stock in a constructive momentum range. RYTM's beta is 1.24, indicating greater market sensitivity than the broad market.
What Changed in RYTM?
The largest recent change in RYTM is Momentum moving up by 14.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the RYTM Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RYTM Decision Framework
Public evidence layers, setup checks, and risk context for Rhythm Pharmaceuticals, Inc..
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis
Rhythm Pharmaceuticals, Inc. has an AIQ Score of 62/100 in a Neutral regime. Momentum is strongest at 72/100. Beta is 1.24, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RYTM is in a Neutral AIQ regime with score 62/100. |
| Signal Conflict | The primary conflict is that momentum leads at 72/100 while value lags at 52/100. |
| Factor Evidence | Momentum 72/100 · Value 52/100 · Quality 60/100 · Risk 57/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 72/100.
Momentum is 72/100 and RSI (14) is 66.3.
RYTM is in a Neutral regime at 62/100.
Risk factor is 57/100 with beta 1.24 and annual volatility 54.57%.
Current conflict: momentum leads at 72/100 while value lags at 52/100.
RYTM Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RYTM Fundamentals
RYTM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RYTM Technical Analysis
RYTM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RYTM Stock Catalysts
Track RYTM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RYTM Dividend Analysis
RYTM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RYTM Financial Data
RYTM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RYTM Risk Analysis
RYTM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RYTM Stock News
RYTM stock news, market tone, recent headlines, and catalyst context.
RYTM vs Biotechnology Peers
Current peer cohort: RYTM · SEPN · SLS · SMMT · SNDX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RYTM Current stock | 62/100 | 52/100 | 72/100 | 57/100 | 0.52 | 54.57% | Current |
| SEPN Septerna Inc | 69/100 | 55/100 | 87/100 | 52/100 | 1.43 | 69.35% | RYTM vs SEPN |
| SLS SELLAS Life Sciences Group, Inc. | 57/100 | — | 55/100 | 32/100 | 2.04 | 109.89% | RYTM vs SLS |
| SMMT Summit Therapeutics Inc. | 47/100 | — | 65/100 | 38/100 | -0.01 | 75.92% | RYTM vs SMMT |
| SNDX Syndax Pharmaceuticals, Inc. | 43/100 | 64/100 | 14/100 | 37/100 | -0.76 | 57.16% | RYTM vs SNDX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for RYTM: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RYTM
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RYTM
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RYTM Stock FAQ
What is RYTM stock price today?
Rhythm Pharmaceuticals, Inc.'s current stock price is $115.02. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RYTM bullish or bearish right now?
RYTM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RYTM's market cap?
RYTM's market cap is $7.94B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RYTM's current P/E ratio?
RYTM's current P/E ratio is -39.66 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RYTM's RSI?
RYTM's 14-day RSI is 66.28 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RYTM above its 50-day and 200-day moving averages?
RYTM is 18.72% from its 50-day SMA and 18.28% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RYTM's next earnings date?
RYTM's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RYTM pay a dividend?
RYTM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.